Lorazepam
Ativan, Lorazepam, Loreev (lorazepam) is a small molecule pharmaceutical. Lorazepam was first approved as Ativan on 1982-01-01. It is used to treat anxiety disorders, catatonia, depressive disorder, partial epilepsies, and psychotic disorders amongst others in the USA. It is known to target ovarian cancer G-protein coupled receptor 1 and alpha-1B adrenergic receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Ativan, Lorazepam, Loreev (discontinued: Lorazepam)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lorazepam
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LOREEV XR | Almatica Pharma | N-214826 RX | 2021-08-27 | 4 products, RLD, RS |
| ATIVAN | Bausch Health Companies | N-017794 RX | 1982-01-01 | 3 products, RLD, RS |
| ATIVAN | Hikma Pharmaceuticals | N-018140 RX | 1982-01-01 | 2 products, RLD, RS |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Lorazepam, Loreev Xr, Almatica | |||
| 8999393 | 2034-01-08 | DP | U-3210 |
HCPCS
Code | Description |
|---|---|
| J2060 | Injection, lorazepam, 2 mg |
Clinical
Clinical Trials
179 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 9 | 1 | 1 | 2 | 5 | 17 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | 1 | 3 | 2 | 4 | 4 | 14 |
| Delirium | D003693 | — | R41.0 | 3 | 3 | 1 | 4 | 1 | 11 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | 1 | — | 2 | 5 | — | 8 |
| Psychotic disorders | D011618 | — | F20.81 | — | 1 | 1 | 6 | — | 8 |
| Depression | D003863 | — | F33.9 | — | 1 | 1 | 4 | 1 | 7 |
| Psychomotor agitation | D011595 | — | — | — | 1 | 2 | 4 | 1 | 7 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 1 | — | — | 5 | 1 | 7 |
| Substance withdrawal syndrome | D013375 | EFO_0005800 | — | — | 1 | — | 4 | 2 | 7 |
| Pain | D010146 | EFO_0003843 | R52 | — | 1 | 1 | 1 | 3 | 6 |
Show 40 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Status epilepticus | D013226 | EFO_0008526 | G41 | 1 | 2 | 9 | — | 3 | 14 |
| Neoplasms | D009369 | — | C80 | 1 | 4 | 1 | — | 2 | 7 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | 1 | 2 | 3 | — | — | 6 |
| Seizures | D012640 | — | G40.4 | — | 2 | 4 | — | — | 5 |
| Sleep initiation and maintenance disorders | D007319 | — | F51.01 | — | 2 | 2 | — | — | 4 |
| Dementia | D003704 | EFO_0003862 | F03 | 1 | — | 1 | — | — | 2 |
| Critical illness | D016638 | — | — | — | 1 | 2 | — | — | 2 |
| Vertigo | D014717 | — | H81.39 | — | — | 1 | — | 1 | 2 |
| Dizziness | D004244 | — | R42 | — | — | 1 | — | 1 | 2 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | 1 | — | — | 2 |
Show 8 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 1 | 2 | — | — | 2 | 5 |
| Nausea | D009325 | — | R11.0 | — | 2 | — | — | 2 | 4 |
| Vomiting | D014839 | — | R11.1 | — | 1 | — | — | 2 | 3 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | 1 | — | — | 2 | 3 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | — | 1 | — | — | 2 | 3 |
| Sarcoma | D012509 | — | — | — | 1 | — | — | 1 | 2 |
| Myeloid leukemia acute | D015470 | — | C92.0 | — | 1 | — | — | 1 | 2 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | — | 1 | — | — | 1 | 2 |
| Cocaine-related disorders | D019970 | — | F14 | 1 | 2 | — | — | — | 2 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | 1 | — | — | 1 | 2 |
Show 29 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | — | — | — | 1 | 2 |
| Head and neck neoplasms | D006258 | — | — | 1 | — | — | — | — | 1 |
| Voice disorders | D014832 | — | — | 1 | — | — | — | — | 1 |
| Epidermolysis bullosa | D004820 | — | Q81 | 1 | — | — | — | — | 1 |
| Epidermolysis bullosa dystrophica | D016108 | — | Q81.2 | 1 | — | — | — | — | 1 |
| Respiratory insufficiency | D012131 | — | J96.9 | 1 | — | — | — | — | 1 |
| Emergence delirium | D000071257 | — | — | 1 | — | — | — | — | 1 |
| Neuroimaging | D059906 | — | — | 1 | — | — | — | — | 1 |
| Obsessive-compulsive disorder | D009771 | EFO_0004242 | F42 | 1 | — | — | — | — | 1 |
| Compulsive personality disorder | D003193 | — | F60.5 | 1 | — | — | — | — | 1 |
Show 5 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psychological distress | D000079225 | — | — | — | — | — | — | 3 | 3 |
| Central nervous system neoplasms | D016543 | — | — | — | — | — | — | 2 | 2 |
| Leukemia | D007938 | — | C95 | — | — | — | — | 2 | 2 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | — | — | — | — | 1 | 1 |
| Postoperative nausea and vomiting | D020250 | EFO_0004888 | — | — | — | — | — | 1 | 1 |
| Genetic polymorphism | D011110 | — | — | — | — | — | — | 1 | 1 |
| Germ cell and embryonal neoplasms | D009373 | — | — | — | — | — | — | 1 | 1 |
| Medulloblastoma | D008527 | — | — | — | — | — | — | 1 | 1 |
| Retinoblastoma | D012175 | — | — | — | — | — | — | 1 | 1 |
| Rhabdoid tumor | D018335 | — | — | — | — | — | — | 1 | 1 |
Show 36 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Lorazepam |
| INN | lorazepam |
| Description | Lorazepam is a benzodiazepine. |
| Classification | Small molecule |
| Drug class | antianxiety agents (diazepam type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C1Nc2ccc(Cl)cc2C(c2ccccc2Cl)=NC1O |
Identifiers
| PDB | — |
| CAS-ID | 846-49-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL580 |
| ChEBI ID | — |
| PubChem CID | 3958 |
| DrugBank | DB00186 |
| UNII ID | O26FZP769L (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
GPR68
GPR68
ADRA1B
ADRA1B
Organism
Homo sapiens
Gene name
GPR68
Gene synonyms
OGR1
NCBI Gene ID
Protein name
ovarian cancer G-protein coupled receptor 1
Protein synonyms
G-protein coupled receptor 68, GPR12A, ovarian cancer G protein-coupled receptor, 1, Sphingosylphosphorylcholine receptor
Uniprot ID
Mouse ortholog
Gpr68 (238377)
ovarian cancer G-protein coupled receptor 1 (Q8BFQ3)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Lorazepam
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 19,276 documents
View more details
Safety
Black-box Warning
Black-box warning for: Ativan, Lorazepam, Loreev xr
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
47,865 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use